Seattle Washington Legalizes Psychedelics, Marijuana Rule Changes Coming Up In The US
Voters in more than a dozen Ohio municipalities will decide on ballot measures to decriminalize marijuana next month.
Seattle’s City Council approved a resolution Monday to decriminalize noncommercial activity around a wide range of psychedelic substances, including the cultivation and sharing of psilocybin mushrooms, ayahuasca, ibogaine and non-peyote-derived mescaline.
A Republican Pennsylvania senator and former federal law enforcement agent announced on Monday that he will be filing a bill to legalize marijuana in the state—and he’s asking his colleagues to join him in the effort.
Alabama regulators are moving to amend hemp rules.
MAINE – Following the release of a preliminary/discussion draft of revisions to the Adult Use Marijuana Program (AUMP) rule last month, the Office of Marijuana Policy (OMP) is announcing plans for a rulemaking public hearing and to formally begin the Maine Administrative Procedures Act (MAPA) process for 18-691 C.M.R. ch. 1.
New Mexico regulators proposed and will hold a public hearing on emergency rules about marijuana solvents on October 28.
Colorado regulators will hold a hearing on proposed changes to marijuana rules on November 1st, 2021.
A top Mexican senator says the stage is set for lawmakers to actually pass a marijuana legalization bill during the new session after multiple attempts in recent years fell short of getting over the finish line.
The State of the Evidence on the Association Between State Cannabis Laws and Opioid-Related Outcomes: a Review
Twenty-one US-based studies published between 2014 and 2021 that assessed state cannabis laws’ association with opioid-related outcomes were reviewed. Study results were largely inconclusive. We identified six challenges of existing work: (1) inability to directly measure cannabis/opioid substitution; (2) use of general population samples and lack of individual-level longitudinal studies; (3) challenges disentangling effects of cannabis laws from other state laws; (4) methodological challenges with staggered policy implementation; (5) limited consideration of cannabis law provisions; (6) lack of triangulation across data sources.
While existing research suggests the potential for cannabis laws to reduce high-risk opioid prescribing and other opioid-related adverse outcomes, studies should be interpreted in light of limitations.
Rediscovering Psilocybin as an Antidepressive Treatment Strategy
There has recently been a renewal of interest in psychedelic research on the use of psilocybin in psychiatric treatment and, in particular, for the treatment of major depressive disorder (MDD). Several state-of-the-art studies have provided new insight into the mechanisms of action of psilocybin and its therapeutic potential. Nevertheless, many questions remain unanswered. With this review, we provide an overview of the current state of research on the potential mechanisms of psilocybin, its antidepressant potential, and the associated risks and adverse effects, to provide an update on a controversial topic discussed in psychopharmacology.